Drug · DIN 02435136
SYLVANT
SINGLE-USE VIAL
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since July 30, 2024; first marketed March 3, 2015.
- Drug Identification Number (DIN)
- 02435136
- Company (DIN owner)
- Recordati Rare Diseases Canada IncToronto, Ontario, Canada
- Schedule
- Schedule d; Prescription
- Dosage form
- Powder For Solution
- Route
- Intravenous
- Therapeutic class (ATC)
- Siltuximab L04AC11
- Class
- Human
- Record last updated
- August 12, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| SILTUXIMAB | 400 MG | VIAL |
Notices of Compliance
Health Canada approvals that name this DIN.
- July 30, 2024: NOC 33724New Drug Submission (NDS) · Administrative - Change in Product Ownership
- January 26, 2021: NOC 25123New Drug Submission (NDS) · Administrative - change in product ownership
- December 3, 2014: NOC 16402New Drug Submission (NDS)
Recalls and safety alerts that mention it
Health Canada’s recall notices do not carry licence numbers, so these are matched by name: notices whose title or product names “sylvant”. A notice may cover another product or only some lots: read it to see what it covers.
- Sylvant 400mg: Affected lot is labelled with the incorrect expiry date found on the vial and carton.May 2, 2025 · Drugs · Product quality · Type III
Other DINs named SYLVANT
- DIN 02435128 · Marketed